摘要
目的探讨溶瘤病毒与丝裂霉素联合应用对膀胱癌T-24细胞体内外生长的抑制效应和机制。方法将溶瘤病毒不同的感染复数或与丝裂霉素(0.1mg/L)联合应用,通过细胞生长抑制实验及裸鼠皮下移植瘤模型,观察其对膀胱癌T-24细胞的作用及其机制。结果与单独应用相比,溶瘤病毒与低剂量的MMC联合可明显抑制T-24细胞体外生长,诱导T-24细胞凋亡,裸鼠体内肿瘤发生时间延迟,4周后肿瘤体积与单独应用时相比,差异有显著性(P<0.05)。与体外处理结果一致。结论溶瘤病毒与MMC联合应用可显著增强MMC对T-24细胞的杀伤作用,进一步提高膀胱癌的疗效。
Objective To evaluate the effect of combined use of oncolytic virus and the chemotherapeutic agents mitomycin （MMC） in growth inhibition of human bladder cancer cell line T-24 in vitro. Methods Human bladder cancer cell line T-24 was infected with oncolytic virus （ONYX-015） of different multiplicity of infection, or treated with MMC in addition to ONYX-015. The changes in the cell growth, morphology, and apoptosis of cultured T-24 cells were observed by means of cell counting and fluorescence microscopy after the treatments. The effects of the treatment protocols were also tested in nude mouse model of implanted subcutaneous tumor. Results Combined use of ONYX-015 and MMC produced substantially stronger cytotoxic effect against T-24 cells than exclusive use of ONYX-015. In in vivo experiments, combination of oncolytic virus and MMC resulted in much more significant tumor growth inhibition than either of the agents used alone. Obvious T-24 cell apoptosis could be observed in response to combined ONYX-105 and MMC treatment and exclusive ONYX-105 treatment. Conclusions ONYX-015 combined with MMC can produce significant cytotoxicity against T-24 cells and enhance therapeutic efficacy against bladder carcinoma.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2006年第11期1623-1625,1628,共4页
Journal of Southern Medical University
基金
广东省自然科学基金(020059)~~
关键词
溶瘤病毒
丝裂霉素
膀胱肿瘤
oncolytic virus
mitomycin
bladder neoplasm
carcinoma
